Chairmen Guthrie and Griffith Announce Hearing to Discuss Legislation that Protects American Communities from Emerging Illicit Drug Threats

WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Health, announced a hearing titled Policies to Protect Our Communities from Illicit Drug Threats.

“As new and emerging drug threats arise in communities across America, it’s vital this Committee continues to implement solutions that prevent illicit drugs from causing any more damage for American families,” said Chairmen Guthrie and Griffith. “This hearing builds on critical pieces of legislation that President Trump signed into law last year, like the HALT Fentanyl Act and the SUPPORT for Patients and Communities Reauthorization Act. We will also discuss several additional bills that actively promote the safety of our constituents and crack down on the infiltration of lethal substances into our communities. We are grateful to our bill sponsors for championing these policies, because there is always more that can be done to combat the illicit drug crisis.”

Subcommittee on Health legislative hearing titled Policies to Protect Our Communities From Illicit Drug Threats.

WHAT: Subcommittee on Health legislative hearing on how the Committee is cracking down on illicit drug threats in order to protect Americans families and keep communities safe.

DATE: Thursday, March 26, 2026      

TIME: 2:00 PM ET

LOCATION: 2123 Rayburn House Office Building

This hearing will focus on the following bills: 

  • H.R. 1266Combatting Illicit Xylazine Act (Reps. Panetta and Pfluger)
  • H.R. 5630To amend the Public Health Service Act to require additional information in State plans for Substance Use Prevention, Treatment, and Recovery Services block grants (Rep. Houchin)
  • H.R. 5629To provide that the final rule of the Department of Health and Human Services titled “Medications for the Treatment of Opioid Use Disorder”, except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect. (Rep. Houchin)
  • H.R. 2004Tyler’s Law (Reps. Lieu and Latta)
  • H.R. 7970, STOP Nitazenes Act (Rep. Latta)
  • H.R. 8000END 7-OH Act (Rep. Bilirakis)
  • H.R. 7184PRESS Act (Rep. McDowell)
  • H.R. 8005Stop Pills That Kill Act (Rep. Evans)
  • H.R. 5880Fight Illicit Pill Presses Act (Reps. Hageman and Stansbury)
  • H.R. 1227, Alternatives to Pain Act (Reps. Miller-Meeks and Barragan)
  • H.R. 2715, Destruction of Hazardous Imports Act (Reps. Higgins and Carter)
  • H.R. 1561ALERT Communities Act (Reps. Crockett and Gooden)
  • H.R. 7994, HERO Act (Rep. Ruiz)
  • H.R. 7407Prohibiting Tianeptine and Other Dangerous Products Act of 2026 (Rep. Pallone)

This notice is at the direction of the Chairman. This hearing will be open to the public and press and will be livestreamed at energycommerce.house.gov. If you have any questions about this hearing, please contact Annabelle Huffman with the Committee staff at Annabelle.Huffman@mail.house.gov. If you have any press-related questions, please contact Katie West at Katie.West@mail.house.gov.

###